Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asimadoline for Moderate to Severe Menopausal Vasomotor Symptoms
NCT07042516Phase 2Recruiting
- Sponsor
- Tioga Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in vasomotor symptoms comparing Asimadoline with Placebo (2 arms). Primary endpoint: Safety as Assessed by Adverse Events, Clinical Laboratory Parameters, and Vital Signs at 8 weeks. Started Aug 2025; status: recruiting.
02
Drugs
asimadoline
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT07042516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07042516.